Search

file (3)

Publication Library

Publication Library

HOMEPublication Library

2022.Apr.09

Prodrug

OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death

Poster

2021.Nov.04

Vaccine

The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets

2021.Jul.15

Prodrug

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity

2021.Jun.01

ADC

Preclinical Studies of OBI-999: A Novel Globo H–Targeting Antibody–Drug Conjugate

2021.Apr.10

Vaccine

Inhibitory activity of Globo-H and SSEA-4 on activated T cells

Poster

2021.Apr.10

Prodrug

Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424

Poster

2021.Apr.10

ADC

Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998

Poster

2020.Nov.19

Vaccine

A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients

Poster

2020.Nov.19

Vaccine

OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial

Presentation Slides

2020.Jul.22

Vaccine

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study